Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib + Camrelizumab as First-Line Therapy for PD-L1 Positive R/M HNSCC
ChiCTR2500106336Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivarmacitinib and camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Overall survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ivarmacitinibcamrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500106336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106336.